DE69409641T2 - Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen - Google Patents

Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen

Info

Publication number
DE69409641T2
DE69409641T2 DE69409641T DE69409641T DE69409641T2 DE 69409641 T2 DE69409641 T2 DE 69409641T2 DE 69409641 T DE69409641 T DE 69409641T DE 69409641 T DE69409641 T DE 69409641T DE 69409641 T2 DE69409641 T2 DE 69409641T2
Authority
DE
Germany
Prior art keywords
treatment
halogen
derivatives
indolocarbazol
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69409641T
Other languages
English (en)
Other versions
DE69409641D1 (de
Inventor
Craig DIONNE
Patricia Contreras
Chikara Murakata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE69409641D1 publication Critical patent/DE69409641D1/de
Publication of DE69409641T2 publication Critical patent/DE69409641T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69409641T 1993-05-28 1994-05-27 Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen Expired - Lifetime DE69409641T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6917893A 1993-05-28 1993-05-28
US9662293A 1993-07-22 1993-07-22
PCT/US1994/006082 WO1994027982A1 (en) 1993-05-28 1994-05-27 Use of indolocarbazole derivatives to treat a pathological condition of the prostate

Publications (2)

Publication Number Publication Date
DE69409641D1 DE69409641D1 (de) 1998-05-20
DE69409641T2 true DE69409641T2 (de) 1998-11-26

Family

ID=26749764

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69409641T Expired - Lifetime DE69409641T2 (de) 1993-05-28 1994-05-27 Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen

Country Status (14)

Country Link
US (2) US5516771A (de)
EP (2) EP0699204B1 (de)
JP (2) JP3344586B2 (de)
KR (1) KR100201343B1 (de)
AT (1) ATE165097T1 (de)
AU (1) AU679752B2 (de)
CA (1) CA2163904C (de)
DE (1) DE69409641T2 (de)
DK (1) DK0699204T3 (de)
ES (1) ES2118414T3 (de)
FI (2) FI113537B (de)
NO (1) NO306902B1 (de)
NZ (1) NZ267337A (de)
WO (1) WO1994027982A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
DK0695755T3 (da) * 1994-08-04 1999-06-28 Hoffmann La Roche Pyrrolocarbazoler
US5686444A (en) * 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
NZ332645A (en) 1996-05-01 2000-07-28 Lilly Co Eli use of a bis-indolylmaleimide derivative for treating VEGF related diseases
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
ATE224718T1 (de) 1996-06-25 2002-10-15 Cephalon Inc Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
HUP0003194A3 (en) * 1997-08-15 2003-03-28 Cephalon Inc West Chester Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
US6093713A (en) 1997-12-31 2000-07-25 Kyowa, Hakko, Kogyo Co., Ltd. 3'-epimeric K-252A derivatives
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1126855B1 (de) 1998-09-25 2007-05-09 Cephalon, Inc. Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
ES2316194T3 (es) * 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. Metodos para la regulacion de la angiogenesis y la integridad vascular utilizando los ligandos bdnf, nt-3 y nt-4.
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
WO2001010440A1 (en) * 1999-08-09 2001-02-15 Trustees Of Dartmouth College COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US7018999B2 (en) * 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
WO2007042286A1 (en) 2005-10-11 2007-04-19 Merck Patent Gmbh Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
KR102228358B1 (ko) 2012-12-21 2021-03-16 쉬케후세트 솔란데트 에이치에프 신경 장애 및 통증의 ｅｇｆｒ 표적 치료

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62240689A (ja) * 1986-04-07 1987-10-21 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質誘導体及びその製法
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
EP0303697B1 (de) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivate des physiologisch aktiven mittels k-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
NZ242467A (en) * 1991-07-03 1995-06-27 Regeneron Pharma Methods and compositions using oligonucleotides to treat mammalian tumour cells expressing neurotrophic factors
AU3064992A (en) * 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US6271242B1 (en) * 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders

Also Published As

Publication number Publication date
WO1994027982A1 (en) 1994-12-08
JP3727613B2 (ja) 2005-12-14
FI955709A (fi) 1996-01-03
FI20031516A (fi) 2003-10-16
NO954816L (no) 1996-01-26
EP0699204A1 (de) 1996-03-06
NO306902B1 (no) 2000-01-10
CA2163904C (en) 2000-01-25
AU6960794A (en) 1994-12-20
DK0699204T3 (da) 1999-02-22
JP2002356487A (ja) 2002-12-13
EP0839814A3 (de) 1998-09-16
FI955709A0 (fi) 1995-11-27
EP0839814A2 (de) 1998-05-06
JP3344586B2 (ja) 2002-11-11
US5654427A (en) 1997-08-05
AU679752B2 (en) 1997-07-10
FI113537B (fi) 2004-05-14
EP0699204B1 (de) 1998-04-15
FI114864B (fi) 2005-01-14
CA2163904A1 (en) 1994-12-08
ES2118414T3 (es) 1998-09-16
NO954816D0 (no) 1995-11-27
KR960702838A (ko) 1996-05-23
NZ267337A (en) 2005-01-28
US5516771A (en) 1996-05-14
DE69409641D1 (de) 1998-05-20
JP2002504064A (ja) 2002-02-05
KR100201343B1 (ko) 1999-06-15
EP0699204A4 (de) 1996-01-10
ATE165097T1 (de) 1998-05-15

Similar Documents

Publication Publication Date Title
DE69409641D1 (de) Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
FI914723A0 (fi) 17b-substituerade 4-aza-5a-androstan -3-jon-derivat och foerfarande foer framstaellning av desamma.
FR2391183A1 (fr) Hydroxyalkylphenones et leur application comme photosensibilisateurs
ATE152111T1 (de) K-252a derivate
FI911443A0 (fi) Foerfarande foer framstaellning av 3,5-di-tert.butyl-4-hydroxifenylmetylenderivat av 2-substituerade tiazolidinoner, oxazolidinoner och imidazolidinoner med antiinflammatorisk aktivitet.
ATE319440T1 (de) Antidiabetische mittel
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
DE69104593D1 (de) Herstellung und Verwendung von N-Jodopropargyl-oxycarbonylaminosäure-Estern als antimicrobielle Mittel.
ES2193241T3 (es) Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas.
DE3072187D1 (de) Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung.
BG101109A (en) Thiopyridyl compounds for controlling helicobacter bacteria
DE69502223T2 (de) Neue Verwendung von 1Alpha-fluor-25-hydroxy-16-en-23-yn-cholecalciferol
ATE111100T1 (de) Imidazochinoxalinverbindungen und ihre herstellung und verwendung.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE59109225D1 (de) Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE3867652D1 (de) N-substituierte 3,4-dihydropyrimidinverbindungen als mittel zur behandlung von erkrankungen des kardiovaskularen systems.
ES2061794T3 (es) Nuevos derivados de benzazepina.
FI810145L (fi) Nya substituerade 1,8-dihydroxi-9-(10h)antracenoner foerfarande foer deras framstaellning och dessa foereningar innehaollande laekemedel
ATE153340T1 (de) Cyathane derivate und diese enthaltende nervenwachstumsfaktor produktion stimulatoren und antimikrobielle mittel
DE50115225D1 (de) Verfahren zur Herstellung von Beta-Hydroxyalkylamiden
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
DE59303840D1 (de) Schabenbekämpfungsverfahren und Mittel zur Bekämpfung von Schaben
NO884431D0 (no) Fremgangsmaate for fremstilling av heterocykliske forbindelser.
ATE28876T1 (de) Triorganozinnacetylsalicylate und diese enthaltende biozide mittel.
DE59208712D1 (de) Neue cytarabin-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition